About: Association between Angiotensin-Converting Enzyme Inhibitors and Lung Cancer—A Nationwide, Population-Based, Propensity Score-Matched Cohort Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Association between Angiotensin-Converting Enzyme Inhibitors and Lung Cancer—A Nationwide, Population-Based, Propensity Score-Matched Cohort Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Association between Angiotensin-Converting Enzyme Inhibitors and Lung Cancer—A Nationwide, Population-Based, Propensity Score-Matched Cohort Study
Creator	Lin, Cheng-Chieh Kao, Chia-Hung Lin, Chia-Der Hsu, Wu-Huei Lin, Cheng-Li Lin, Shih-Yi Wang, I.-Kuan Hsu, Chung-Y
Source	Medline; PMC
abstract	Background: Direct evidence of lung cancer risk in Asian users of angiotensin-converting enzyme inhibitors (ACEIs) is lacking. Methods: The ACEI cohort comprised 22,384 patients aged ≥ 18 years with a first prescription of ACEI. The comparison angiotensin receptor blocker (ARB) cohort consisted of age-, sex- and comorbidity-matched patients at a ratio of 1:1. The primary outcome was the incidence of lung cancer, which was evaluated using a proportional hazard model. Results: The overall incidence rates of lung cancer in the ACEI and ARB cohorts were 16.6 and 12.2 per 10,000 person-years, respectively. The ACEI cohort had a significantly higher risk of lung cancer than the ARB cohort (adjusted hazard ratio [aHR]. = 1.36; 95% confidence interval [CI]. = 1.11–1.67). Duration–response and dose–response analyses revealed that compared with patients who did not receive ACEIs, patients who received ACEIs for more than 45 days per year (aHR = 1.87; 95% CI = 1.48–2.36) and patients who received more than 540 defined daily doses of ACEIs per year (aHR =1.80; 95% CI = 1.43–-2.27) had a significantly higher risk of lung cancer. The cumulative incidence of lung cancer was also significantly higher in the ACEI cohort than in the ARB cohort (log-rank test, p = 0.002). Conclusions: ACEI use is associated with an increased risk of lung cancer compared with ARB use. Patients using ARBs have a significantly lower risk of lung cancer than non-ARB users.
has issue date	2020-03-21(xsd:dateTime)
bibo:doi	10.3390/cancers12030747
bibo:pmid	32245239
has license	cc-by
sha1sum (hex)	d7c667bcfa6796ea4001a378c1e567d25e55efd2
schema:url	https://doi.org/10.3390/cancers12030747
resource representing a document's title	Association between Angiotensin-Converting Enzyme Inhibitors and Lung Cancer—A Nationwide, Population-Based, Propensity Score-Matched Cohort Study
has PubMed Central identifier	PMC7140054
has PubMed identifier	32245239
schema:publication	Cancers (Basel)
resource representing a document's body	covid:d7c667bcfa6796ea4001a378c1e567d25e55efd2#body_text
is schema:about of	named entity 'evaluated' named entity 'ACEI' named entity 'aHR' named entity 'The' named entity 'ASIAN' named entity 'DOSES' named entity 'RECEIVED' named entity 'age' named entity 'The' named entity 'ACEI' named entity 'risk' named entity 'ACEI' named entity 'ARBs' named entity 'incidence' named entity 'Study' named entity 'Lung' named entity 'Inhibitors' named entity 'incidence rates' named entity 'ARB' named entity 'ARB' named entity 'lung cancer' named entity 'lung cancer' named entity 'comorbidity' named entity 'lung cancer' named entity 'ARBs' named entity 'ACEI' named entity 'ARB' named entity 'ARB' named entity 'antihypertensive' named entity 'Cohort studies' named entity 'lungs' named entity 'ACEIs' named entity 'ACEI' named entity 'incidence rates' named entity 'ACEI' named entity 'α-blockers' named entity 'Mann-Whitney U test' named entity 'ACEI' named entity 'follow-up' named entity 'cumulative incidence' named entity 'chronic obstructive pulmonary disease' named entity 'China Medical University' named entity 'ACEIs' named entity 'substance P' named entity 'gene' named entity 'RAS' named entity 'lung cancer' named entity 'end point' named entity 'metastasis' named entity 'ACEI' named entity 'lung cancer' named entity 'lungs' named entity 'Asian' named entity 'pancreatic cancer' named entity 'ACEI' named entity 'risk factors' named entity 'Health Insurance' named entity 'bradykinin' named entity 'metastasis' named entity 'lungs' named entity 'infarction' named entity 'lung tumors' named entity 'proteinuria' named entity 'RAS' named entity 'tumor cells' named entity 'left ventricular dysfunction' named entity 'air pollutants' named entity 'Cary, NC' named entity 'ACEI' named entity 'kidney function' named entity 'secondhand smoke' named entity 'log-rank test' named entity 'Institutional Review Board' named entity 'metastasis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software